FOLH1 and metastatic malignant neoplasm: Among them, PSMA (also known as glutamate carboxypeptidase II), a type II transmembrane glycoprotein has a significant potential for both imaging and therapeutics in prostate cancer as it is upregulated 100~1000-fold higher in prostate cancer cells compared to healthy prostate cells and even more expressed in aggressive/metastatic cancers [11,12,13].